An experimental obesity drug shows promise in early trials
An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothold in the obesity market.
The drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months, according to an abstract posted Friday ahead of the American Diabetes Assn. conference in Chicago. The drug is moving to the next stage of development and researchers will present details on dosing and safety at the conference next week.
'The data look particularly strong, and should push the program back into investor conversations,' Cantor Fitzgerald analyst Prakhar Agrawal wrote in a note to investors.
Lilly has shared few details about eloralintide before now, because it's still in the early stages of testing. It's part of a class of drugs that mimic the hormone amylin, which slows digestion and makes people feel full longer. They're thought to be a gentler option for losing weight than currently available injections like Zepbound and Wegovy, which often have side effects like nausea and vomiting.
The study enrolled 100 patients who were given different doses of the experimental drug or a placebo for 12 weeks. Weight loss ranged from 2.6% to 11.3%, according to the abstract. Gastrointestinal side effects were relatively minimal, with about 10% of patients experiencing diarrhea and 8% vomiting. Few details were provided, however, including information on risks and benefits based on dose.
The promise of drugs that are easier to take than blockbusters like Lilly's Zepbound and its rival Wegovy, from Novo Nordisk A/S, has drawn increasing interest from companies hoping for a piece of pharma's hottest market.
In March, Roche Holding AG entered into a $5.3-billion deal to co-develop and commercialize Zealand Pharma A/S' amylin drug, called petrelintide. It is seen as the one to beat in the amylin class, with early trials showing patients lost as much as 8.6% of their body weight in four months, with less nausea than Lilly and Novo's current therapies.
AbbVie Inc. agreed to pay as much as $2.2 billion in March for an amylin drug from Danish biotech Gubra A/S, marking its first foray into the obesity market. New York-based startup Metsera Inc. is developing a related compound that may be taken less frequently than weekly shots like Zepbound and Wegovy.
Lilly is already a leader in the obesity market, where Zepbound is capturing the majority of new prescriptions. The company has several promising next-generation products in the late stages of development, including a pill called orforglipron and an experimental shot that's thought to be even more effective for weight loss.
The company is studying eloralintide alone and in combination with Zepbound — similar to the approach Novo is taking with its next-generation drug CagriSema, which combines an amylin component with semaglutide, the backbone of Wegovy and the diabetes drug Ozempic.
Muller writes for Bloomberg.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
New to The Street's Show #672 Airs Tonight on Fox Business Network at 10:30 PM EST
Featured as Sponsored Programming: FLOKI, BioVie Inc. (NASDAQ:BIVI), NRX Pharmaceuticals (NASDAQ:NRXP), and Vita Bella NEW YORK CITY, NEW YORK / / June 16, 2025 / New to The Street, a premier financial media platform, announces the nationwide broadcast of Show #672 airing tonight at 10:30 PM EST on the Fox Business Network. This nationally televised episode features long-form interviews with four dynamic companies, offering investors a front-row seat to market-moving innovation and growth. Featured companies on tonight's show include: FLOKI - The popular Web3 ecosystem continues to lead with utility and community engagement. FLOKI's highly anticipated Valhalla metaverse game officially launches on June 30, marking a major milestone for the project's play-to-earn vision and cementing its role in the next generation of crypto gaming. BioVie Inc. (NASDAQ:BIVI) - A clinical-stage biopharmaceutical innovator advancing treatments in neurodegenerative and liver diseases. With multiple Phase 3 trials underway, BioVie is positioned as a leader in the Alzheimer's and hepatology therapeutic categories. NRX Pharmaceuticals (NASDAQ:NRXP) - A cutting-edge life sciences company developing novel therapies for treatment-resistant depression and pulmonary disorders. NRX's pipeline includes breakthrough-stage compounds with FDA fast-track designations and real-world impact potential. Vita Bella - A rising name in health and lifestyle, Vita Bella delivers premium nutrition and wellness products tailored for modern consumers seeking vitality, beauty, and balance. Each interview explores the companies' strategic goals, innovation roadmaps, and value propositions, offering clarity and visibility to investors across retail and institutional markets. "Show #672 highlights the diversity of innovation happening across Web3, biotech, and wellness," said Vince Caruso, CEO and Creator of New to The Street. "With FLOKI's Valhalla launch on the horizon and biotech milestones accelerating, this lineup demonstrates how vision meets execution." About New to The StreetNew to The Street is one of the longest-running business television platforms in the U.S., delivering sponsored content and earned media since 2009. Weekly broadcasts on Fox Business Network and Bloomberg Television reach over 220 million households, supplemented by 2.65 million YouTube subscribers and a combined social media audience of over 700,000 followers across LinkedIn, Instagram, Facebook, and X. Its proprietary ecosystem integrates national TV exposure, digital reach, NYC outdoor billboards, and earned media pickups on ABC, NBC, and CBS affiliate networks. Media Contact:Monica BrennanPublic Relations - New to The StreetMonica@ SOURCE: New To The Street View the original press release on ACCESS Newswire
CBS News
2 hours ago
- CBS News
Aging LGBTQ+ community finds unique challenges providing care for loved ones
Many older members of LGBTQ+ population dealing with stress of caregiving Many older members of LGBTQ+ population dealing with stress of caregiving Many older members of LGBTQ+ population dealing with stress of caregiving New York City represents the largest LGBTQ+ population in the country, with more than 700,000 residents. Many encounter unique challenges as they age and provide care for their loved ones. In this installment of CBS News New York's Cost of Caregiving series, reporter Jennifer Bisram takes a close look at the community-wide issues, resources and how chosen family plays a pivotal role. Read more: Geriatric care improvements needed immediately in New York, doctors say Matt Sullivan's story Matt Sullivan's husband, Ken, who was an artist, died back in 2020 from a 9/11-related cancer. "The biggest struggle is the loss of a best friend, and my life is still on the walls with his paintings," said Sullivan, a 76-year-old retired professor. He showed CBS News New York the Manhattan apartment filled with memories that they shared together, and remembered becoming his partner's caregiver. "It was really challenging. I had no idea what I was up for. Life was about trying to stay up with him while maintaining my own life," Sullivan said. Sullivan said the loss was even harder without family support. These days, he's aging alone in his New York City home. "I came out to my family at 18. It was illegal for me to be gay. They could have put me in an institution," Sullivan said. "It's really the loneliness and, especially in my case, I've been abandoned by family and truly alone, and I can speak for those suffering ... love given and not being returned." Sullivan said his parents and brother passed on and his only living sibling disowned him for being gay. "My brother considers me an evil person and not aligned with his belief system," Sullivan said. The mission of SAGE -- Advocacy and Services for LGBTQ+ Elders According to the Family Caregiver Alliance, older adults in the LGBTQ+ community are twice as likely to be single and live alone and are three times less likely to have children. As a result, nearly two-thirds of older LGBTQ+ adults consider their friends to be their chosen family. "I gained strength from my friends, my gay friends," Sullivan said. SAGE -- Advocacy and Services for LGBTQ+ Elders is one of the oldest and largest organizations dedicated to aging LGBTQ+ elders and caregivers. "We offer support groups, counseling, care management, help with supplementals like respite and supplies they might need," said Ernesto Finales, SAGE's director of care management. SAGE has four senior centers across New York City, including one in Midtown. Recent studies show older LGBTQ+ adults experience social, financial, physical and mental health disparities, including health care and housing discrimination and social isolation. They're also at risk for developing chronic diseases. "When you prolong care or avoid health care, makes chronic issues more present, more likely to happen," Finales said. According to a recent Equal Rights Center report, 48% of older same-sex couples applying for elder housing say they were subjected to discrimination. "Every single step you have to come out and disclose your LGBTQIA status, part of that has a fear of marginalization and discrimination, which is based on genuine lived experience," Finales said. Another recent study also shows 88% of LGBTQ+ older adults say they'd feel more comfortable with long-term care services if they knew the staff had been trained about the needs of LGBTQ+ patients. Read more: Help is available for New Yorkers caring for loved ones whose health is declining "I've never done this, never really faced it" It's all too familiar for Sullivan, who broke down at one point during his interview with CBS News New York. "I've never done this, never really faced it," Sullivan said. "We learn to deal with loneliness because of people who judge us." Later, he said, "Thank you for helping me also deal with what I'm going through cause you brought out a part of me that I don't talk about very much." Now, as an aging New Yorker, he says he'll rely on his chosen family. "Loneliness, financial insecurity, which I'm going through, some of that, getting around, I may have to use a walker now because of all the falls I've taken," Sullivan said. He said he'll continue to advocate for LGBTQ+ rights and encourage the older generation who struggled with social stigmas their entire lives. "I have a new life in speaking out now as a senior gay man," Sullivan said.
Yahoo
2 hours ago
- Yahoo
Feinstein Institutes Awarded $2.3M, Joins Global Bipolar Disorder Research Network
MANHASSET, N.Y., June 16, 2025--(BUSINESS WIRE)--To continue its groundbreaking bipolar disorder research, Northwell Health's The Feinstein Institutes for Medical Research has been awarded $2.3 million and joined the Breakthrough Discoveries for Thriving with Bipolar Disorder (BD²) Integrated Network, a national collaborative research and clinical care initiative aimed at transforming treatment and care for people living with bipolar disorder. Led by Caitlin Millett, PhD, assistant professor in the Feinstein Institutes' Institute of Behavioral Science, the site is located at Northwell Health's Zucker Hillside Hospital in Glen Oaks. The BD² Integrated Network's novel approach is a collaborative effort to drive scientific advancements by focusing on improving patient care in near-real time through cutting-edge biotechnology, big data analytics and an unprecedented data ecosystem to address bipolar disorder. The Feinstein Institutes joins nine other institutions, including the University of Cincinnati/Lindner Center of HOPE, University of California San Diego and The University of Texas at Austin as part of this national research collaboration. "With this grant, we will contribute to a deeper understanding about bipolar disorder, with a focus on addressing the challenges of diagnosis and treatment.," said Dr. Millett. "We also hope to expand access to effective care for our patients." Bipolar disorder is a complex and heterogeneous disorder, and more than 70% of people with bipolar disorder are misdiagnosed at least once. It takes seven years on average to diagnose bipolar disorder, and less than 50% of those who are diagnosed find an effective treatment. The research from each of these sites will involve both a large-scale longitudinal study and a learning health network model, allowing for continuous feedback between research findings and clinical practice. This approach aims to translate research discoveries into improved patient care more efficiently, and will focus on in-depth patient characterization, adherence to clinical guidelines and integration of research and clinical activities. "Bipolar disorder is often misdiagnosed and effective treatments remain elusive for many living with it," said Anil K. Malhotra, MD, co-director and professor of the Feinstein Institutes' Institute of Behavioral Science and vice chair for research with the Department of Psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. "This funding allows us to contribute to a national effort to improve diagnosis, treatment, and ultimately, the lives of those affected by this complex disorder." About the Feinstein Institutes The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program. For more information about how we produce knowledge to cure disease, visit and follow us on LinkedIn. View source version on Contacts Julianne Mosher Allen516-880-4824jmosherallen@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
